140 related articles for article (PubMed ID: 37879140)
21. Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection.
Klimke A; Hefner G; Will B; Voss U
Med Hypotheses; 2020 Sep; 142():109783. PubMed ID: 32402766
[TBL] [Abstract][Full Text] [Related]
22. Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19.
Lei ZN; Wu ZX; Dong S; Yang DH; Zhang L; Ke Z; Zou C; Chen ZS
Pharmacol Ther; 2020 Dec; 216():107672. PubMed ID: 32910933
[TBL] [Abstract][Full Text] [Related]
23. A computational study on hydroxychloroquine binding to target proteins related to SARS-COV-2 infection.
Navya VB; Hosur MV
Inform Med Unlocked; 2021; 26():100714. PubMed ID: 34458558
[TBL] [Abstract][Full Text] [Related]
24. EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA.
Delen LA; Gok A; Kasapoglu US; Cagasar O; Gok Z; Berber N; Derya S; Tetik B
Acta Clin Croat; 2022 Nov; 61(3):403-411. PubMed ID: 37492367
[TBL] [Abstract][Full Text] [Related]
25. Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study.
Maiti S; Banerjee A
Drug Dev Res; 2021 Feb; 82(1):86-96. PubMed ID: 32770567
[TBL] [Abstract][Full Text] [Related]
26. Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering.
Di Castelnuovo A; Gialluisi A; Antinori A; Berselli N; Blandi L; Bonaccio M; Bruno R; Cauda R; Costanzo S; Guaraldi G; Menicanti L; Mennuni M; My I; Parruti G; Patti G; Perlini S; Santilli F; Signorelli C; Stefanini G; Vergori A; Ageno W; Agodi A; Agostoni P; Aiello L; Al Moghazi S; Arboretti R; Aucella F; Barbieri G; Barchitta M; Bonfanti P; Cacciatore F; Caiano L; Cannata F; Carrozzi L; Cascio A; Castiglione G; Ciccullo A; Cingolani A; Cipollone F; Colomba C; Colombo C; Crisetti A; Crosta F; Danzi GB; D'Ardes D; de Gaetano Donati K; Di Gennaro F; Di Tano G; D'Offizi G; Fusco FM; Gaudiosi C; Gentile I; Gianfagna F; Giuliano G; Graziani E; Guarnieri G; Langella V; Larizza G; Leone A; Maccagni G; Magni F; Maitan S; Mancarella S; Manuele R; Mapelli M; Maragna R; Marcucci R; Maresca G; Marongiu S; Marotta C; Marra L; Mastroianni F; Mengozzi A; Meschiari M; Milic J; Minutolo F; Mussinelli R; Mussini C; Musso M; Odone A; Olivieri M; Palimodde A; Pasi E; Pesavento R; Petri F; Pivato CA; Poletti V; Ravaglia C; Righetti G; Rognoni A; Rossato M; Rossi I; Rossi M; Sabena A; Salinaro F; Sangiovanni V; Sanrocco C; Schiano Moriello N; Scorzolini L; Sgariglia R; Simeone PG; Spinicci M; Tamburrini E; Torti C; Trecarichi EM; Vettor R; Vianello A; Vinceti M; Virdis A; De Caterina R; Iacoviello L
J Healthc Eng; 2021; 2021():5556207. PubMed ID: 34336157
[TBL] [Abstract][Full Text] [Related]
27. Outside any therapeutic trial prescription of hydroxychloroquine for hospitalized patients with covid-19 during the first wave of the pandemic: A national inquiry of prescription patterns among French hospitalists.
Bosquet A; Affo C; Plaisance L; Poenou G; Mortier E; Mahé I
PLoS One; 2022; 17(1):e0261843. PubMed ID: 35061735
[TBL] [Abstract][Full Text] [Related]
28. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
Nina PB; Dash AP
Indian J Public Health; 2020 Jun; 64(Supplement):S125-S127. PubMed ID: 32496241
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro.
Ni Y; Liao J; Qian Z; Wu C; Zhang X; Zhang J; Xie Y; Jiang S
Bioorg Med Chem; 2022 Jan; 53():116523. PubMed ID: 34875467
[TBL] [Abstract][Full Text] [Related]
30. A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS-CoV-2(-)/(+) populations.
Steinbronn C; Chhonker YS; Stewart J; Leingang H; Heller KB; Krows ML; Paasche-Orlow M; Bershteyn A; Stankiewicz Karita HC; Agrawal V; Laufer M; Landovitz R; Wener M; Murry DJ; Johnston C; Barnabas RV; Arnold SLM
Clin Transl Sci; 2023 Jul; 16(7):1243-1257. PubMed ID: 37118968
[TBL] [Abstract][Full Text] [Related]
31. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.
Maisonnasse P; Guedj J; Contreras V; Behillil S; Solas C; Marlin R; Naninck T; Pizzorno A; Lemaitre J; Gonçalves A; Kahlaoui N; Terrier O; Fang RHT; Enouf V; Dereuddre-Bosquet N; Brisebarre A; Touret F; Chapon C; Hoen B; Lina B; Calatrava MR; van der Werf S; de Lamballerie X; Le Grand R
Nature; 2020 Sep; 585(7826):584-587. PubMed ID: 32698191
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19.
Zahr N; Urien S; Llopis B; Pourcher V; Paccoud O; Bleibtreu A; Mayaux J; Gandjbakhch E; Hekimian G; Combes A; Benveniste O; Saadoun D; Allenbach Y; Pinna B; Cacoub P; Funck-Brentano C; Salem JE
Therapie; 2021; 76(4):285-295. PubMed ID: 33558079
[TBL] [Abstract][Full Text] [Related]
33. Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?
Pahan P; Pahan K
J Neuroimmune Pharmacol; 2020 Jun; 15(2):174-180. PubMed ID: 32415419
[TBL] [Abstract][Full Text] [Related]
34. Molecular basis for drug repurposing to study the interface of the S protein in SARS-CoV-2 and human ACE2 through docking, characterization, and molecular dynamics for natural drug candidates.
Alazmi M; Motwalli O
J Mol Model; 2020 Nov; 26(12):338. PubMed ID: 33175236
[TBL] [Abstract][Full Text] [Related]
35. Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study.
Saib A; Amara W; Wang P; Cattan S; Dellal A; Regaieg K; Nahon S; Nallet O; Nguyen LS
PLoS One; 2021; 16(6):e0252388. PubMed ID: 34106964
[TBL] [Abstract][Full Text] [Related]
36. Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19.
Cui C; Tu S; En VSJ; Li X; Yao X; Li H; Liu D
Curr Drug Metab; 2020; 21(6):427-435. PubMed ID: 32520683
[TBL] [Abstract][Full Text] [Related]
37. Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?
Derwand R; Scholz M
Med Hypotheses; 2020 Sep; 142():109815. PubMed ID: 32408070
[TBL] [Abstract][Full Text] [Related]
38. Hydroxychloroquine in patients with novel coronavirus infection (COVID-19): a case-control study.
Kamalov AA; Mareev VY; Orlova YA; Plisyk AG; Akopyan ZA; Mareev YV; Mershina EA; Begrambekova YL; Pakhomov PV
Kardiologiia; 2021 Mar; 61(2):28-39. PubMed ID: 33734044
[TBL] [Abstract][Full Text] [Related]
39. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
40. The Rise and Fall of Hydroxychloroquine for the Treatment and Prevention of COVID-19.
Lee Z; Rayner CR; Forrest JI; Nachega JB; Senchaudhuri E; Mills EJ
Am J Trop Med Hyg; 2021 Jan; 104(1):35-38. PubMed ID: 33236703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
